# Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

> **NCT06158100** · PHASE1 · SUSPENDED · sponsor: **Antonio M Jimenez Jimenez** · enrollment: 25 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **BIOLOGICAL:** Donor Lymphocyte Infusion

## Key facts

- **NCT ID:** NCT06158100
- **Lead sponsor:** Antonio M Jimenez Jimenez
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-12-04
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** Funding Sponsor decision due to review of efficacy data from other trials involving investigational product.
- **Last updated:** 2025-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158100, "Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06158100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*